Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Evaluating the optimal duration of CPX-351 treatment & best timing for alloSCT consolidation in AML

Fabio Guolo • 10 Dec 2023
ASH 2023
Acute Myeloid Leukemia Leukemia CPX-351

Fabio Guolo, MD, University of Genoa, Genoa, Italy, shares insights into a real-world Italian study exploring the optimal duration of treatment with CPX-351 in patients with both transplant-eligible and transplant-ineligible acute myeloid leukemia (AML). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Fabio Guolo

1:25
Low bone marrow cellularity predicts hematologic AEs to CPX-351 in AML
Fabio Guolo • 10 Dec 2023
2:55
Post-transplant PD1 blockade plus autologous lymphocytes in R/R HL
Fabio Guolo • 10 Dec 2023
3:10
Novel AML treament approaches
Fabio Guolo • 10 Jun 2020
2:26
Prognostic relevance of a BPDCN-like immunophenotype in cytogenetically normal AML
Fabio Guolo • 11 Jun 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals